Pasar al contenido principal

COMPLICACIONES TEMPRANAS EN LA ENFERMEDAD DE ALZHEIMER Y EN DIABETES MELLITUS TIPO 2: IMPLICACIONES FARMACOLOGICAS

PID2020-115499RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE CADIZ

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glycogen synthase kinase‑3β inhibitor VP3.15 ameliorates neurogenesis, neuronal loss and cognitive impairment in a model of germinal matrix‑intraventricular hemorrhage of the preterm newborn

  • Atienza-Navarro, Isabel
  • Marco, Ángel del
  • Alves-Martínez, Pilar
  • Garcia‑Perez, Maria de los Angeles
  • Raya‑Marin, Alvaro
  • Benavente-Fernandez, Isabel
  • Gil, Carmen
  • Martínez Gil, Ana
  • Lubián-López, Simón P.
  • García-Alloza, Mónica
17 p.-5 fig., Advances in neonatology have significantly reduced mortality rates due to prematurity. However, complications of prematurity have barely changed in recent decades. Germinal matrix-intraventricular hemorrhage (GM-IVH) is one of the most severe complications of prematurity, and these children are prone to suffer short- and long-term sequelae, including cerebral palsy, cognitive and motor impairments, or neuropsychiatric disorders. Nevertheless, GM-IVH has no successful treatment. VP3.15 is a small, heterocyclic molecule of the 5-imino-1,2,4-thiadiazole family with a dual action as a phosphodiesterase 7 and glycogen synthase kinase-3β (GSK-3β) inhibitor. VP3.15 reduces neuroinflammation and neuronal loss in other neurodegenerative disorders and might ameliorate complications associated with GM-IVH. We administered VP3.15 to a mouse model of GM-IVH. VP3.15 reduces the presence of hemorrhages and microglia in the short (P14) and long (P110) term. It ameliorates brain atrophy and ventricle enlargement while limiting tau hyperphosphorylation and neuronal and myelin basic protein loss. VP3.15 also improves proliferation and neurogenesis as well as cognition after the insult. Interestingly, plasma gelsolin levels, a feasible biomarker of brain damage, improved after VP3.15 treatment. Altogether, our data support the beneficial effects of VP3.15 in GM-IVH by ameliorating brain neuroinflammatory, vascular and white matter damage, ultimately improving cognitive impairment associated with GM-IVH., Funding for open access publishing: Universidad de Cádiz/CBUA This work was supported by a predoctoral fellowship. Instituto de Investigacion Biomedica de la Provincia de Cadiz (INIBICA) (PAM), Agencia Andaluza del Conocimiento. Proyectos I + D + I—Programa Operativo FEDER Andalucía 2014–2020 fondos FEDER (SOL-201800107189-TRA). Ministerio de Ciencia e Innovación. Programa Estatal de Generacion de Conocimiento y Fortalecimiento Cientifico y Tecnologico del Sistema de I + D + i y del Programa Estatal de I + D + i Orientada a los Retos de la Sociedad, del Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion (PID2020-115499RB-I00). Proyectos de I + D + i, en régimen de concurrencia competitiva, destinadas a las universidades y entidades públicas de investigación calificadas como agentes del Sistema Andaluz del Conocimiento, en el ámbito del Plan Andaluz de Investigación, Desarrollo e Innovación (PAIDI 2020). Andalucia se mueve con Europa (P20-00928) (MGA)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Accelerated amyloid angiopathy and related vascular alterations in a mixed murine model of Alzheimer's disease and type two diabetes

  • Vargas-Soria, Maria
  • Ramos-Rodriguez, Juan Jose
  • Del Marco, Angel|||0000-0001-7911-2395
  • Hierro-Bujalance, Carmen
  • Carranza-Naval, Maria Jose
  • Calvo-Rodriguez, Maria
  • van Veluw, Susanne J.
  • Stitt, Alan W.|||0000-0002-8647-9918
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Bacskai, Brian J.
  • Infante-Garcia, Carmen
  • Garcia-Alloza, Monica|||0000-0003-1610-4114
While aging is the main risk factor for Alzheimer's disease (AD), emerging evidence suggests that metabolic alterations such as type 2 diabetes (T2D) are also major contributors. Indeed, several studies have described a close relationship between AD and T2D with clinical evidence showing that both diseases coexist. A hallmark pathological event in AD is amyloid-β (Aβ) deposition in the brain as either amyloid plaques or around leptomeningeal and cortical arterioles, thus constituting cerebral amyloid angiopathy (CAA). CAA is observed in 85-95% of autopsy cases with AD and it contributes to AD pathology by limiting perivascular drainage of Aβ. To further explore these alterations when AD and T2D coexist, we have used in vivo multiphoton microscopy to analyze over time the Aβ deposition in the form of plaques and CAA in a relevant model of AD (APPswe/PS1dE9) combined with T2D (db/db). We have simultaneously assessed the effects of high-fat diet-induced prediabetes in AD mice. Since both plaques and CAA are implicated in oxidative-stress mediated vascular damage in the brain, as well as in the activation of matrix metalloproteinases (MMP), we have also analyzed oxidative stress by Amplex Red oxidation, MMP activity by DQ ™ Gelatin, and vascular functionality. We found that prediabetes accelerates amyloid plaque and CAA deposition, suggesting that initial metabolic alterations may directly affect AD pathology. T2D significantly affects vascular pathology and CAA deposition, which is increased in AD-T2D mice, suggesting that T2D favors vascular accumulation of Aβ. Moreover, T2D synergistically contributes to increase CAA mediated oxidative stress and MMP activation, affecting red blood cell velocity. Our data support the cross-talk between metabolic disease and Aβ deposition that affects vascular integrity, ultimately contributing to AD pathology and related functional changes in the brain microvasculature.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Effects of diabetes on microglial physiology: a systematic review of in vitro, preclinical and clinical studies

  • Vargas Soria, María
  • García Alloza, Mónica
  • Corraliza Gómez, Miriam
Diabetes mellitus is a heterogeneous chronic metabolic disorder characterized by the presence of hyperglycemia, commonly preceded by a prediabetic state. The excess of blood glucose can damage multiple organs, including the brain. In fact, cognitive decline and dementia are increasingly being recognized as important comorbidities of diabetes. Despite the largely consistent link between diabetes and dementia, the underlying causes of neurodegeneration in diabetic patients remain to be elucidated. A common factor for almost all neurological disorders is neuroinflammation, a complex inflammatory process in the central nervous system for the most part orchestrated by microglial cells, the main representatives of the immune system in the brain. In this context, our research question aimed to understand how diabetes affects brain and/or retinal microglia physiology. We conducted a systematic search in PubMed and Web of Science to identify research items addressing the effects of diabetes on microglial phenotypic modulation, including critical neuroinflammatory mediators and their pathways. The literature search yielded 1327 records, including 18 patents. Based on the title and abstracts, 830 papers were screened from which 250 primary research papers met the eligibility criteria (original research articles with patients or with a strict diabetes model without comorbidities, that included direct data about microglia in the brain or retina), and 17 additional research papers were included through forward and backward citations, resulting in a total of 267 primary research articles included in the scoping systematic review. We reviewed all primary publications investigating the effects of diabetes and/or its main pathophysiological traits on microglia, including in vitro studies, preclinical models of diabetes and clinical studies on diabetic patients. Although a strict classification of microglia remains elusive given their capacity to adapt to the environment and their morphological, ultrastructural and molecular dynamism, diabetes modulates microglial phenotypic states, triggering specific responses that include upregulation of activity markers (such as Iba1, CD11b, CD68, MHC-II and F4/80), morphological shift to amoeboid shape, secretion of a wide variety of cytokines and chemokines, metabolic reprogramming and generalized increase of oxidative stress. Pathways commonly activated by diabetes-related conditions include NF-κB, NLRP3 inflammasome, fractalkine/CX3CR1, MAPKs, AGEs/RAGE and Akt/mTOR. Altogether, the detailed portrait of complex interactions between diabetes and microglia physiology presented here can be regarded as an important starting point for future research focused on the microglia–metabolism interface., 30 páginas
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Glycogen Synthase Kinase‑3β Inhibitor VP3.15 Ameliorates Neurogenesis, Neuronal Loss and Cognitive Impairment in a Model of Germinal Matrix‑intraventricular Hemorrhage of the Preterm Newborn

  • Atienza Navarro, Isabel
  • Marco Delgado, Ángel José del
  • Alves Martinez, Pilar
  • García Pérez, María de los Ángeles
  • Raya Marín, Álvaro
  • Benavente Fernández, Isabel
  • Gil, Carmen
  • Martínez, Ana
  • Lubián López, Simón Pedro
  • García Alloza, Mónica
Advances in neonatology have significantly reduced mortality rates due to prematurity. However, complications of prema- turity have barely changed in recent decades. Germinal matrix-intraventricular hemorrhage (GM-IVH) is one of the most severe complications of prematurity, and these children are prone to suffer short- and long-term sequelae, including cerebral palsy, cognitive and motor impairments, or neuropsychiatric disorders. Nevertheless, GM-IVH has no successful treatment. VP3.15 is a small, heterocyclic molecule of the 5-imino-1,2,4-thiadiazole family with a dual action as a phosphodiesterase 7 and glycogen synthase kinase-3β (GSK-3β) inhibitor. VP3.15 reduces neuroinflammation and neuronal loss in other neuro- degenerative disorders and might ameliorate complications associated with GM-IVH. We administered VP3.15 to a mouse model of GM-IVH. VP3.15 reduces the presence of hemorrhages and microglia in the short (P14) and long (P110) term. It ameliorates brain atrophy and ventricle enlargement while limiting tau hyperphosphorylation and neuronal and myelin basic protein loss. VP3.15 also improves proliferation and neurogenesis as well as cognition after the insult. Interestingly, plasma gelsolin levels, a feasible biomarker of brain damage, improved after VP3.15 treatment. Altogether, our data support the beneficial effects of VP3.15 in GM-IVH by ameliorating brain neuroinflammatory, vascular and white matter damage, ultimately improving cognitive impairment associated with GM-IVH
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Empagliflozin reduces brain pathology in Alzheimer’s disease and type 2 diabetes

  • Hierro Bujalance, Carmen
  • García Alloza, Mónica
Alzheimer’s disease (AD) and type 2 diabetes (T2D): More than 55 million people suffer from dementia, and it is expected that over 150 million people will suffer from this disease by 2050. AD is the most common type of dementia and while aging remains the main risk factor to suffer it, previous studies have also shown that metabolic disorders, and T2D specifically, are also major contributors (Wang et al., 2012). The prevalence of diabetes has reached 537 million people worldwide and these figures are expected to keep rising (Ahmad et al., 2022). All things considered, both diseases are a great challenge for health.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Caffeine Restores Neuronal Damage and Inflammatory Response in a Model of Intraventricular Hemorrhage of the Preterm Newborn

  • Alves Martinez, Pilar
  • Atienza Navarro, Isabel
  • Vargas Soria, María
  • Carranza Naval, María José
  • Infante-Garcia, Carmen
  • Benavente Fernández, Isabel
  • Marco Delgado, Ángel José del
  • Lubián López, Simón Pedro
  • García Alloza, Mónica
Germinal matrix-intraventricular hemorrhage (GM-IVH) is the most frequent intracranial hemorrhage in the preterm infant (PT). Long-term GM-IVH-associated sequelae include cerebral palsy, sensory and motor impairment, learning disabilities, or neuropsychiatric disorders. The societal and health burden associated with GM-IVH is worsened by the fact that there is no successful treatment to limit or reduce brain damage and neurodevelopment disabilities. Caffeine (Caf) is a methylxanthine that binds to adenosine receptors, regularly used to treat the apnea of prematurity. While previous studies support the beneficial effects at the brain level of Caf in PT, there are no studies that specifically focus on the role of Caf in GM-IVH. Therefore, to further understand the role of Caf in GM-IVH, we have analyzed two doses of Caf (10 and 20 mg/kg) in a murine model of the disease. We have analyzed the short (P14) and long (P70) effects of the treatment on brain atrophy and neuron wellbeing, including density, curvature, and phospho-tau/total tau ratio. We have analyzed proliferation and neurogenesis, as well as microglia and hemorrhage burdens. We have also assessed the long-term effects of Caf treatment at cognitive level. To induce GM-IVH, we have administered intraventricular collagenase to P7 CD1 mice and have analyzed these animals in the short (P14) and long (P70) term. Caf showed a general neuroprotective effect in our model of GM-IVH of the PT. In our study, Caf administration diminishes brain atrophy and ventricle enlargement. Likewise, Caf limits neuronal damage, including neurite curvature and tau phosphorylation. It also contributes to maintaining neurogenesis in the subventricular zone, a neurogenic niche that is severely affected after GM-IVH. Furthermore, Caf ameliorates small vessel bleeding and inflammation in both the cortex and the subventricular zone. Observed mitigation of brain pathological features commonly associated with GM-IVH also results in a significant improvement of learning and memory abilities in the long term. Altogether, our data support the promising effects of Caf to reduce central nervous system complications associated with GM-IVH.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Tesis doctoral (DoctoralThesis)

Neuroprotective effects of the dual glycogen synthase kinase-3b and phosphodiesterase 7 inhibitor VP3.15 and of an enriched environment in germinal matrix-intraventricular hemorrhage

  • Atienza Navarro, Isabel
Advances in neonatology have significantly reduced mortality rates associated with prematurity. Nevertheless, the incidence and impact of its complications have remained largely unchanged in recent decades, mainly due to the increased survival of extremely preterm newborn (PT). Germinal matrix-intraventricular hemorrhage (GMIVH) is one of the most common and severe complications of prematurity. As a result, PT frequently experience short- and long-term sequelae. These impairments include cerebral palsy, cognitive and motor deficits, or neuropsychiatric disorders. Despite the significant economic, social, and emotional impact of this pathology, there is currently no effective treatment for GM-IVH. PT continue to face an urgent need for new therapeutic approaches to prevent or reduce associated brain and behavioral complications VP3.15 is a small heterocyclic molecule belonging to the 5-imino-1,2,4- thiadiazole family, with a dual action as a glycogen synthase kinase-3β (GSK-3β) and phosphodiesterase 7 (PDE7) inhibitor. It has demonstrated neuroprotective and antiinflammatory effects in other neurodegenerative disorders. Given its promising properties, VP3.15 may represent a potential therapeutic strategy to reduce complications associated with GM-IVH, so we studied the short- and long-term effects of VP3.15 in a murine model that recapitulates the complications of this prematurityrelated pathology. On the other hand, previous studies have shown that early intervention programs may have beneficial effects in PT, comparable to those observed in enriched environments (EE) in animal models. Therefore, we also studied the effects of long-term exposure to a complex EE in a murine model of GM-IVH, and we also analyzed clinically relevant biomarkers of GM-IVH in patients following an intervention program focused on parental bonding and stimulation. We have used a murine model of GM-IVH induced by intraventricular unilateral administration of collagenase (Col) to P7 CD1 mice, who received 7 consecutive days of i.p. VP3.15 treatment. We analyzed the short (P14) and long-term (P110) effects of VP3.15 on brain and cerebellar pathology as well as behavioral complications. Our results showed that VP3.15 treatment limited brain atrophy by reducing ventricular enlargement and cortical thinning, while it also preserved corpus callosum volume and increased myelin basic protein (MBP) levels. VP3.15 ameliorated neuronal loss and maintained Purkinje cell arborization. In addition, the treatment decreased tau hyperphosphorylation and enhanced proliferation and neurogenesis. VP3.15 also prevented the spread of the hemorrhage to the periventricular region, reduced the presence of hemorrhages and hemosiderin deposition, and contributed to preserve blood brain barrier (BBB) integrity. Moreover, VP3.15 restored cerebrospinal fluid (CSF) circulation across several brain areas and reduced the presence of microglia, ultimately leading to improve cognitive and motor outcomes following the insult. Interestingly, plasma gelsolin levels (p-GSL), a feasible biomarker of brain damage, improved after VP3.15 treatment. Altogether, our data support the promising effects of VP3.15 to halt and reduce central nervous system complications associated with GM-IVH of the PT. In parallel, we assessed the long-term effects (P70) of an early exposure to EE in the same mouse model. EE exposure attenuated brain atrophy, preserved neuronal density, limited axonal damage and increased neuronal complexity. Additionally, it promoted neurogenesis and attenuated the inflammatory response. Importantly, the exposure to EE led to improvements in cognitive performance, alongside normalization of peripheral markers of brain damage, such as ubiquitin carboxyterminal hydrolase L1 (UCHL1) and p-GSL, in treated animals. In parallel, plasma levels of GFAP, NfL and UCHL1, decreased over time in controls and in patients with GM-IVH. Notably, plasma tau levels, a marker of neuronal damage, were significantly reduced in those patients with GM-IVH who received parental support and nurturing environment whereas p-GSL levels were increased. Altogether, our findings demonstrate that early interventions such as EE or parental support improve key pathological features, peripheral biomarkers, and cognitive outcomes associated with GM-IVH, highlighting their therapeutic potential in both preclinical and clinical contexts., Los avances en neonatología han reducido significativamente las tasas de mortalidad asociadas a la prematuridad. Sin embargo, la incidencia y el impacto de sus complicaciones han permanecido prácticamente inalterados en las últimas décadas, principalmente debido a la mayor supervivencia de los recién nacidos prematuros (PT) extremos. La hemorragia intraventricular de matriz germinal (GM-IVH) es una de las complicaciones más frecuentes y graves de la prematuridad. Como consecuencia, los PT experimentan con frecuencia secuelas a corto y largo plazo. Estas secuelas incluyen parálisis cerebral, déficits cognitivos y motores o trastornos neuropsiquiátricos. A pesar del gran impacto económico, social y emocional de esta patología, actualmente no existe ningún tratamiento eficaz para la GM-IVH, y los PT siguen teniendo la necesidad urgente de nuevos enfoques terapéuticos para prevenir o reducir las complicaciones cerebrales y conductuales. VP3.15 es una pequeña molécula heterocíclica de la familia de los 5-imino-1,2,4- tiadiazoles con doble acción como inhibidor de la glucógeno sintasa quinasa-3β (GSK3β) y de la fosfodiesterasa 7 (PDE7). Ha demostrado efectos neuroprotectores y antiinflamatorios en otros trastornos neurodegenerativos. Dadas sus prometedoras propiedades, VP3.15 puede proporcionar una estrategia terapéutica para reducir las complicaciones asociadas a la GM-IVH, por lo que hemos estudiado sus efectos a corto y largo plazo en un modelo murino que reproduce las complicaciones de esta patología. Por otro lado, estudios previos han demostrado que los programas de intervención temprana pueden tener efectos beneficiosos en el PT, comparables a los observados con entornos enriquecidos (EE) en modelos animales. Por lo tanto, también hemos estudiado los efectos de la exposición a largo plazo a un EE complejo en un modelo murino de GM-IVH. Paralelamente hemos analizado biomarcadores clínicamente relevantes de GM-IVH en pacientes que seguían un programa de intervención centrado en el vínculo y la estimulación parentales. Hemos utilizado un modelo murino de GM-IVH inducido mediante la administración intraventricular unilateral de colagenasa (Col) a ratones CD1 a P7, que recibieron tratamiento i.p. con VP3.15 durante 7 días. Analizamos los efectos a corto (P14) y largo plazo (P110) de VP3.15 sobre la patología cerebral y cerebelosa, así como las complicaciones conductuales. Nuestros resultados mostraron que el tratamiento con VP3.15 limita la atrofia cerebral reduciendo el ensanchamiento ventricular y el adelgazamiento cortical, mientras que también preserva el volumen del cuerpo calloso y aumenta los niveles de la proteína básica de mielina (MBP). El tratamiento con VP3.15 limita la pérdida neuronal y la simplificación de la arborización de las células de Purkinje. Además, el tratamiento disminuye la hiperfosforilación de tau y aumenta la proliferación y la neurogénesis. VP3.15 también impide la propagación de la hemorragia a la región periventricular, reduce la presencia de hemorragias y el depósito de hemosiderina, y contribuye a preservar la integridad de la barrera hematoencefálica (BBB). Del mismo modo, VP3.15 restablece la circulación del líquido cefalorraquídeo (CSF) en diferentes regiones cerebrales y reduce la presencia de microglía, lo que en última instancia conduce a una mejora de los procesos cognitivos y motores tras la lesión. Además, los niveles plasmáticos de gelsolina (p-GSL), un posible biomarcador de daño neuronal, mejoran tras el tratamiento con VP3.15. En conjunto, nuestros datos apoyan los efectos prometedores de VP3.15 para detener y reducir las complicaciones del sistema nervioso central asociadas con GM-IVH del PT. Paralelamente, evaluamos los efectos a largo plazo (P70) de una exposición temprana a un EE en el mismo modelo de ratón. La exposición a un EE atenuó la atrofia cerebral, preservó la densidad neuronal, limitó el daño axonal y contribuyó a mantener la complejidad neuronal. Además, promovió la neurogénesis y atenuó la respuesta inflamatoria. Es importante destacar que la exposición a EE también produjo mejoras en el rendimiento cognitivo, junto con la normalización de marcadores periféricos de daño cerebral, como la ubiquitina carboxiterminal hidrolasa L1 (UCHL1) y p-GSL, en los animales tratados. Del mismo modo, los niveles plasmáticos de GFAP, NfL y UCHL1, disminuyeron con el tiempo en los pacientes control y en los pacientes con GM-IVH. En particular, los niveles plasmáticos de tau, un marcador de daño neuronal, se redujeron significativamente en aquellos pacientes con GM-IVH que recibieron apoyo parental y un entorno enriquecido, mientras que nos niveles de p-GSL aumentaron. En conjunto, nuestros hallazgos demuestran que la intervención temprana, con un EE o el apoyo parental, mejoran características patológicas clave, biomarcadores periféricos y los procesos cognitivos tras una GM-IVH, destacando su potencial terapéutico tanto en contextos preclínicos como clínicos.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Accelerated amyloid angiopathy and related vascular alterations in a mixed murine model of Alzheimer´s disease and type two diabetes

  • Vargas Soria, María
  • Ramos-Rodríguez, Juan José
  • Marco Delgado, Ángel José del
  • Hierro Bujalance, Carmen
  • Carranza Naval, María José
  • Calvo-Rodriguez, Maria
  • van Veluw, Susanne J.
  • Stitt, Alan W.
  • Simó, Rafael
  • Bacskai, Brian J.
  • Infante-Garcia, Carmen
  • García Alloza, Mónica
Background While aging is the main risk factor for Alzheimer ' s disease (AD), emerging evidence suggests that metabolic alterations such as type 2 diabetes (T2D) are also major contributors. Indeed, several studies have described a close relationship between AD and T2D with clinical evidence showing that both diseases coexist. A hallmark pathological event in AD is amyloid-beta (A beta) deposition in the brain as either amyloid plaques or around leptomeningeal and cortical arterioles, thus constituting cerebral amyloid angiopathy (CAA). CAA is observed in 85-95% of autopsy cases with AD and it contributes to AD pathology by limiting perivascular drainage of A beta. Methods To further explore these alterations when AD and T2D coexist, we have used in vivo multiphoton microscopy to analyze over time the A beta deposition in the form of plaques and CAA in a relevant model of AD (APPswe/PS1dE9) combined with T2D (db/db). We have simultaneously assessed the effects of high-fat diet-induced prediabetes in AD mice. Since both plaques and CAA are implicated in oxidative-stress mediated vascular damage in the brain, as well as in the activation of matrix metalloproteinases (MMP), we have also analyzed oxidative stress by Amplex Red oxidation, MMP activity by DQ((TM)) Gelatin, and vascular functionality. Results We found that prediabetes accelerates amyloid plaque and CAA deposition, suggesting that initial metabolic alterations may directly affect AD pathology. T2D significantly affects vascular pathology and CAA deposition, which is increased in AD-T2D mice, suggesting that T2D favors vascular accumulation of A beta. Moreover, T2D synergistically contributes to increase CAA mediated oxidative stress and MMP activation, affecting red blood cell velocity. Conclusions Our data support the cross-talk between metabolic disease and A beta deposition that affects vascular integrity, ultimately contributing to AD pathology and related functional changes in the brain microvasculature.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Liraglutide Reduces Vascular Damage, Neuronal Loss, and Cognitive Impairment in a Mixed Murine Model of Alzheimer's Disease and Type 2 Diabetes

  • Carranza Naval, María José
  • Marco Delgado, Ángel José del
  • Hierro Bujalance, Carmen
  • Alves Martinez, Pilar
  • Infante-Garcia, Carmen
  • Vargas Soria, María
  • Herrera, Marta
  • Barba Córdoba, Belén
  • Atienza Navarro, Isabel
  • Lubián López, Simón Pedro
  • García Alloza, Mónica
Alzheimer's disease is the most common form of dementia, and epidemiological studies support that type 2 diabetes (T2D) is a major contributor. The relationship between both diseases and the fact that Alzheimer's disease (AD) does not have a successful treatment support the study on antidiabetic drugs limiting or slowing down brain complications in AD. Among these, liraglutide (LRGT), a glucagon-like peptide-1 agonist, is currently being tested in patients with AD in the Evaluating Liraglutide in Alzheimer's Disease (ELAD) clinical trial. However, the effects of LRGT on brain pathology when AD and T2D coexist have not been assessed. We have administered LRGT (500 mu g/kg/day) to a mixed murine model of AD and T2D (APP/PS1xdb/db mice) for 20 weeks. We have evaluated metabolic parameters as well as the effects of LRGT on learning and memory. Postmortem analysis included assessment of brain amyloid-beta and tau pathologies, microglia activation, spontaneous bleeding and neuronal loss, as well as insulin and insulin-like growth factor 1 receptors. LRGT treatment reduced glucose levels in diabetic mice (db/db and APP/PS1xdb/db) after 4 weeks of treatment. LRGT also helped to maintain insulin levels after 8 weeks of treatment. While we did not detect any effects on cortical insulin or insulin-like growth factor 1 receptor m-RNA levels, LRGT significantly reduced brain atrophy in the db/db and APP/PS1xdb/db mice. LRGT treatment also rescued neuron density in the APP/PS1xdb/db mice in the proximity (p = 0.008) far from amyloid plaques (p < 0.001). LRGT reduced amyloid plaque burden in the APP/PS1 animals (p < 0.001), as well as A beta aggregates levels (p = 0.046), and tau hyperphosphorylation (p = 0.009) in the APP/PS1xdb/db mice. Spontaneous bleeding was also ameliorated in the APP/PS1xdb/db animals (p = 0.012), and microglia burden was reduced in the proximity of amyloid plaques in the APP/PS1 and APP/PS1xdb/db mice (p < 0.001), while microglia was reduced in areas far from amyloid plaques in the db/db and APP/PS1xdb/db mice (p < 0.001). This overall improvement helped to rescue cognitive impairment in AD-T2D mice in the new object discrimination test (p < 0.001) and Morris water maze (p < 0.001). Altogether, our data support the role of LRGT in reduction of associated brain complications when T2D and AD occur simultaneously, as regularly observed in the clinical arena., CH-B: predoctoral fellowship. University of Cadiz. PA-M: predoctoral fellowship. Instituto de Investigacion Biomedica de la Provincia de Cadiz (INIBICA). MG-A: Agencia Estatal de Investigacion. Ministerio de Ciencia e Innovacion. Programa Estatal de Generacion de Conocimiento y Fortalecimiento Cientifico y Tecnologico del Sistema de I C D C i y del Programa Estatal de I + D + i Orientada a los Retos de la Sociedad, del Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion 2017-2020 (PID2020115499RB-I0). Programa Estatal de I C D C I orientada a los Retos de la Sociedad (BFU 2016-75038-R), financed by the Agencia Estatal de Investigacion (AEI) and the Fondo Europeo de Desarrollo Regional (FEDER), Ministerio de Ciencia, Innovacion y Universidades. Subvencion para la financiacion de la Investigacion y la Innovacion Biomedica y en Ciencias de la Salud en el Marco de la Iniciativa Territorial Integrada 2014-2020 para la Provincia de Cadiz. Consejeria de Salud. Junta de Andalucia. Union Europea, financed by the Fondo de Desarrollo Regional (FEDER) (PI-0008-2017).
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Effect of caffeine in the intraventricular hemorrhage of the preterm newborn

  • Alves Martinez, Pilar
  • García Alloza, Mónica
There are around 15 million preterm newborns (PT) every year (Atienza-Navarro et al., 2020).